866-997-4948(US-Canada Toll Free)

Ovarian Cancer Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Apr 2013

Category :

Ovarian Cancer

No. of Pages : 329 Pages

 

Global Markets Directs, \'Ovarian Cancer Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ovarian Cancer. 

 

Ovarian Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

  • A snapshot of the global therapeutic scenario for Ovarian Cancer.
  • A review of the Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Ovarian Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

 

Reasons to buy

 

  • Identify and understand important and diverse types of therapeutics under development for Ovarian Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Ovarian Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents


Table of Contents 2
List of Tables 7
List of Figures 12
Introduction 13
Global Markets Direct Report Coverage 13
Ovarian Cancer Overview 14
Therapeutics Development 15
An Overview of Pipeline Products for Ovarian Cancer 15
Ovarian Cancer Therapeutics under Development by Companies 17
Ovarian Cancer Therapeutics under Investigation by Universities/Institutes 31
Late Stage Products 35
Comparative Analysis 35
Mid Clinical Stage Products 36
Comparative Analysis 36
Early Clinical Stage Products 37
Comparative Analysis 37
Discovery and Pre-Clinical Stage Products 38
Comparative Analysis 38
Ovarian Cancer Therapeutics Products under Development by Companies 39
Ovarian Cancer Therapeutics Products under Investigation by Universities/Institutes 58
Companies Involved in Ovarian Cancer Therapeutics Development 62
Bristol-Myers Squibb Company 62
Johnson & Johnson 63
Boehringer Ingelheim GmbH 64
F. Hoffmann-La Roche Ltd. 65
Kyowa Hakko Kirin Co., Ltd. 66
Amgen Inc. 67
Sanofi-Aventis 68
AstraZeneca PLC 69
Eli Lilly and Company 70
Viralytics Ltd. 71
GlaxoSmithKline plc 72
Bioniche Life Sciences, Inc. 73
Tekmira Pharmaceuticals Corp. 74
Genentech, Inc. 75
Nektar Therapeutics 76
Bavarian Nordic A/S 77
Daiichi Sankyo Company, Ltd 78
Merck & Co., Inc. 79
AbGenomics International, Inc. 80
FASgen, Inc. 81
Dainippon Sumitomo Pharma Co., Ltd. 82
Oxford BioMedica plc 83
Generex Biotechnology Corporation 84
Amorfix Life Sciences Ltd. 85
Prolexys Pharmaceuticals, Inc. 86
Aposense Ltd. 87
Millennium Pharmaceuticals, Inc. 88
Novartis AG 89
Samyang Corporation 90
Aphios Corporation 91
Astellas Pharma Inc. 92
Chong Kun Dang Pharmaceutical 93
Eisai Co., Ltd. 94
ImmunoGen, Inc. 95
Pfizer Inc. 96
Sigma-Tau S.p.A. 97
Sunesis Pharmaceuticals, Inc. 98
SuperGen, Inc. 99
Taiho Pharmaceutical Co., Ltd. 100
Cell Therapeutics, Inc. 101
Santaris Pharma A/S 102
Exelixis, Inc. 103
Aduro BioTech 104
Menarini Group 105
Alfacell Corporation 106
Celgene Corporation 107
Onyx Pharmaceuticals, Inc. 108
Bayer AG 109
AntiCancer, Inc. 110
Merck KGaA 111
Access Pharmaceuticals, Inc. 112
Advaxis, Inc. 113
Neogenix Oncology Corporation 114
EntreMed, Inc. 115
Hana Biosciences, Inc. 116
Celldex Therapeutics, Inc. 117
ValiRx Plc 118
AEterna Zentaris Inc. 119
ImmunoCellular Therapeutics, Ltd. 120
IMMUNOMEDICS, INC 121
Lorus Therapeutics Inc 122
Marshall Edwards, Inc. 123
AVAX Technologies, Inc. 124
Basilea Pharmaceutica Ltd. 125
Bionomics Limited 126
Northwest Biotherapeutics, Inc. 127
Novogen Limited 128
Cleveland BioLabs, Inc. 129
Oncolytics Biotech Inc. 130
OXiGENE, Inc. 131
Critical Outcome Technologies Inc. 132
Alnylam Pharmaceuticals, Inc 133
Cytokinetics, Inc 134
Telik, Inc. 135
VioQuest Pharmaceuticals, Inc. 136
Oncogenex Pharmaceuticals, Inc. 137
Dendreon Corporation 138
Prima BioMed Limited 139
Progen Pharmaceuticals Limited 140
Innocell Corporation 141
PharmaGap Inc. 142
Quest PharmaTech Inc. 143
Synta Pharmaceuticals Corp. 144
ThromboGenics NV 145
Oasmia Pharmaceutical AB 146
RXi Pharmaceuticals Corporation 147
Rexahn Pharmaceuticals, Inc. 148
Morphotek, Inc. 149
Cancer Research Technology Limited 150
Spectrum Pharmaceuticals, Inc. 151
Chipscreen Biosciences Ltd 152
Supratek Pharma Inc. 153
GANYMED Pharmaceuticals AG 154
Acceleron Pharma, Inc. 155
Nerviano Medical Sciences S.r.l. 156
Glycotope GmbH 157
TRION Pharma GmbH 158
Advantagene, Inc. 159
BioNumerik Pharmaceuticals, Inc. 160
Alethia Biotherapeutics Inc. 161
OnKor Pharmaceuticals, Inc. 162
Coronado Biosciences, Inc. 163
Cerulean Pharma, Inc. 164
Heat Biologics, Inc. 165
MacroGenics, Inc. 166
Fresenius Biotech GmbH 167
Pantarhei Bioscience BV 168
Azaya Therapeutics, Inc. 169
CanBas Co., Ltd. 170
Merrimack Pharmaceuticals, Inc. 171
Spirogen Ltd. 172
Neotropix, Inc. 173
Innate Therapeutics Limited 174
Conatus Pharmaceuticals Inc. 175
CritiTech, Inc. 176
Deciphera Pharmaceuticals, LLC 177
Vascular Biogenics Ltd. 178
BioCancell Therapeutics, Inc. 179
Advenchen Laboratories, LLC 180
Onconova Therapeutics, Inc 181
MolMed S.p.A. 182
Viral Genetics, Inc. 183
Immunotope, Inc. 184
Esperance Pharmaceuticals, Inc. 185
Omeros Corporation 186
Bolder Biotechnology, Inc. 187
ImmunoVaccine Technologies Inc. 188
Welichem Biotech Inc. 189
Angstrom Pharmaceuticals, Inc. 190
NewLink Genetics Corporation 191
PharmaMar, S.A. 192
TVAX Biomedical, LLC 193
Quintessence Biosciences, Inc. 194
AmpliMed Corporation 195
Tigris Pharmaceuticals, Inc. 196
Viventia Biotechnologies Inc. 197
TRACON Pharmaceuticals, Inc. 198
Medestea Research & Production S.p.A. 199
Domainex Ltd. 200
Anaphore, Inc. 201
Clovis Oncology, Inc. 202
Oncolix, Inc. 203
OHR Pharmaceutical Inc. 204
Cancer Therapeutics CRC Pty Ltd 205
BioProspecting NB, Inc. 206
RECEPTA Biopharma S.A. 207
Bioo Therapeutics 208
Jiangsu Kanion Pharmaceutical Co., Ltd. 209
NovaBioMed Inc 210
PepTx, Inc. 211
Mebiopharm Co., Ltd. 212
DEKK-TEC, Inc. 213
ISA Pharmaceuticals B.V. 214
TAU Therapeutics, LLC 215
Gradalis Inc. 216
Ovarian Cancer Therapeutics Assessment 217
Assessment by Monotherapy Products 217
Assessment by Combination Products 218
Assessment by Route of Administration 219
Assessment by Molecule Type 222
Drug Profiles 225
trebananib - Drug Profile 225
paclitaxel poliglumex - Drug Profile 228
farletuzumab - Drug Profile 232
paclitaxel - Drug Profile 235
canfosfamide hydrochloride - Drug Profile 237
idronoxil - Drug Profile 241
nintedanib - Drug Profile 243
CVac - Drug Profile 245
tirapazamine - Drug Profile 248
vintafolide - Drug Profile 249
vintafolide - Drug Profile 252
idronoxil + [carboplatin] - Drug Profile 255
trebananib + [doxorubicin liposomal] - Drug Profile 257
trabectedin + [doxorubicin liposomal] - Drug Profile 259
cositecan - Drug Profile 260
bevacizumab - Drug Profile 262
bevacizumab - Drug Profile 266
pazopanib hydrochloride - Drug Profile 270
trabectedin - Drug Profile 273
trebananib + [carboplatin] + [paclitaxel] - Drug Profile 276
Ovarian Cancer Therapeutics Drug Profile Updates 278
Ovarian Cancer Therapeutics Discontinued Products 300
Ovarian Cancer Therapeutics - Dormant Products 303
Ovarian Cancer Product Development Milestones 318
Featured News & Press Releases 318
 

Appendix 326
Methodology 326
Coverage 326
Secondary Research 326
Primary Research 326
Expert Panel Validation 326
Contact Us 327
Disclaimer 327

List of Table


Number of Products Under Development for Ovarian Cancer, H1 2013 17
Products under Development for Ovarian Cancer Comparative Analysis, H1 2013 18
Number of Products under Development by Companies, H1 2013 20
Number of Products under Development by Companies, H1 2013 (Contd..1) 21
Number of Products under Development by Companies, H1 2013 (Contd..2) 22
Number of Products under Development by Companies, H1 2013 (Contd..3) 23
Number of Products under Development by Companies, H1 2013 (Contd..4) 24
Number of Products under Development by Companies, H1 2013 (Contd..5) 25
Number of Products under Development by Companies, H1 2013 (Contd..6) 26
Number of Products under Development by Companies, H1 2013 (Contd..7) 27
Number of Products under Development by Companies, H1 2013 (Contd..8) 28
Number of Products under Development by Companies, H1 2013 (Contd..9) 29
Number of Products under Development by Companies, H1 2013 (Contd..10) 30
Number of Products under Development by Companies, H1 2013 (Contd..11) 31
Number of Products under Development by Companies, H1 2013 (Contd..12) 32
Number of Products under Investigation by Universities/Institutes, H1 2013 34
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 35
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 36
Comparative Analysis by Late Stage Development, H1 2013 37
Comparative Analysis by Mid Clinical Stage Development, H1 2013 38
Comparative Analysis by Early Clinical Stage Development, H1 2013 39
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 40
Products under Development by Companies, H1 2013 41
Products under Development by Companies, H1 2013 (Contd..1) 42
Products under Development by Companies, H1 2013 (Contd..2) 43
Products under Development by Companies, H1 2013 (Contd..3) 44
Products under Development by Companies, H1 2013 (Contd..4) 45
Products under Development by Companies, H1 2013 (Contd..5) 46
Products under Development by Companies, H1 2013 (Contd..6) 47
Products under Development by Companies, H1 2013 (Contd..7) 48
Products under Development by Companies, H1 2013 (Contd..8) 49
Products under Development by Companies, H1 2013 (Contd..9) 50
Products under Development by Companies, H1 2013 (Contd..10) 51
Products under Development by Companies, H1 2013 (Contd..11) 52
Products under Development by Companies, H1 2013 (Contd..12) 53
Products under Development by Companies, H1 2013 (Contd..13) 54
Products under Development by Companies, H1 2013 (Contd..14) 55
Products under Development by Companies, H1 2013 (Contd..15) 56
Products under Development by Companies, H1 2013 (Contd..16) 57
Products under Development by Companies, H1 2013 (Contd..17) 58
Products under Development by Companies, H1 2013 (Contd..18) 59
Products under Investigation by Universities/Institutes, H1 2013 60
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 61
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 62
Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 63
Bristol-Myers Squibb Company, H1 2013 64
Johnson & Johnson, H1 2013 65
Boehringer Ingelheim GmbH, H1 2013 66
F. Hoffmann-La Roche Ltd., H1 2013 67
Kyowa Hakko Kirin Co., Ltd., H1 2013 68
Amgen Inc., H1 2013 69
Sanofi-Aventis, H1 2013 70
AstraZeneca PLC, H1 2013 71
Eli Lilly and Company, H1 2013 72
Viralytics Ltd., H1 2013 73
GlaxoSmithKline plc, H1 2013 74
Bioniche Life Sciences, Inc., H1 2013 75
Tekmira Pharmaceuticals Corp., H1 2013 76
Genentech, Inc., H1 2013 77
Nektar Therapeutics, H1 2013 78
Bavarian Nordic A/S, H1 2013 79
Daiichi Sankyo Company, Ltd, H1 2013 80
Merck & Co., Inc., H1 2013 81
AbGenomics International, Inc., H1 2013 82
FASgen, Inc., H1 2013 83
Dainippon Sumitomo Pharma Co., Ltd., H1 2013 84
Oxford BioMedica plc, H1 2013 85
Generex Biotechnology Corporation, H1 2013 86
Amorfix Life Sciences Ltd., H1 2013 87
Prolexys Pharmaceuticals, Inc., H1 2013 88
Aposense Ltd., H1 2013 89
Millennium Pharmaceuticals, Inc., H1 2013 90
Novartis AG, H1 2013 91
Samyang Corporation, H1 2013 92
Aphios Corporation, H1 2013 93
Astellas Pharma Inc., H1 2013 94
Chong Kun Dang Pharmaceutical, H1 2013 95
Eisai Co., Ltd., H1 2013 96
ImmunoGen, Inc., H1 2013 97
Pfizer Inc., H1 2013 98
Sigma-Tau S.p.A., H1 2013 99
Sunesis Pharmaceuticals, Inc., H1 2013 100
SuperGen, Inc., H1 2013 101
Taiho Pharmaceutical Co., Ltd., H1 2013 102
Cell Therapeutics, Inc., H1 2013 103
Santaris Pharma A/S, H1 2013 104
Exelixis, Inc., H1 2013 105
Aduro BioTech, H1 2013 106
Menarini Group, H1 2013 107
Alfacell Corporation, H1 2013 108
Celgene Corporation, H1 2013 109
Onyx Pharmaceuticals, Inc., H1 2013 110
Bayer AG, H1 2013 111
AntiCancer, Inc., H1 2013 112
Merck KGaA, H1 2013 113
Access Pharmaceuticals, Inc., H1 2013 114
Advaxis, Inc., H1 2013 115
Neogenix Oncology Corporation, H1 2013 116
EntreMed, Inc., H1 2013 117
Hana Biosciences, Inc., H1 2013 118
Celldex Therapeutics, Inc., H1 2013 119
ValiRx Plc, H1 2013 120
AEterna Zentaris Inc., H1 2013 121
ImmunoCellular Therapeutics, Ltd., H1 2013 122
IMMUNOMEDICS, INC, H1 2013 123
Lorus Therapeutics Inc, H1 2013 124
Marshall Edwards, Inc., H1 2013 125
Basilea Pharmaceutica Ltd., H1 2013 127
Bionomics Limited, H1 2013 128
Northwest Biotherapeutics, Inc., H1 2013 129
Novogen Limited, H1 2013 130
Cleveland BioLabs, Inc., H1 2013 131
Oncolytics Biotech Inc., H1 2013 132
OXiGENE, Inc., H1 2013 133
Critical Outcome Technologies Inc., H1 2013 134
Alnylam Pharmaceuticals, Inc, H1 2013 135
Cytokinetics, Inc, H1 2013 136
Telik, Inc., H1 2013 137
VioQuest Pharmaceuticals, Inc., H1 2013 138
Oncogenex Pharmaceuticals, Inc., H1 2013 139
Dendreon Corporation, H1 2013 140
Prima BioMed Limited, H1 2013 141
Progen Pharmaceuticals Limited, H1 2013 142
Innocell Corporation, H1 2013 143
PharmaGap Inc., H1 2013 144
Quest PharmaTech Inc., H1 2013 145
Synta Pharmaceuticals Corp., H1 2013 146
ThromboGenics NV, H1 2013 147
Oasmia Pharmaceutical AB, H1 2013 148
Rexahn Pharmaceuticals, Inc., H1 2013 150
Morphotek, Inc., H1 2013 151
Cancer Research Technology Limited, H1 2013 152
Spectrum Pharmaceuticals, Inc., H1 2013 153
Chipscreen Biosciences Ltd, H1 2013 154
Supratek Pharma Inc., H1 2013 155
GANYMED Pharmaceuticals AG, H1 2013 156
Acceleron Pharma, Inc., H1 2013 157
Nerviano Medical Sciences S.r.l., H1 2013 158
TRION Pharma GmbH, H1 2013 160
BioNumerik Pharmaceuticals, Inc., H1 2013 162
Alethia Biotherapeutics Inc., H1 2013 163
OnKor Pharmaceuticals, Inc., H1 2013 164
Coronado Biosciences, Inc., H1 2013 165
Cerulean Pharma, Inc., H1 2013 166
Heat Biologics, Inc., H1 2013 167
MacroGenics, Inc., H1 2013 168
Fresenius Biotech GmbH, H1 2013 169
Pantarhei Bioscience BV, H1 2013 170
Azaya Therapeutics, Inc., H1 2013 171
CanBas Co., Ltd., H1 2013 172
Merrimack Pharmaceuticals, Inc., H1 2013 173
Spirogen Ltd., H1 2013 174
Neotropix, Inc., H1 2013 175
Innate Therapeutics Limited, H1 2013 176
Conatus Pharmaceuticals Inc., H1 2013 177
CritiTech, Inc., H1 2013 178
Deciphera Pharmaceuticals, LLC, H1 2013 179
Vascular Biogenics Ltd., H1 2013 180
BioCancell Therapeutics, Inc., H1 2013 181
Advenchen Laboratories, LLC, H1 2013 182
Onconova Therapeutics, Inc, H1 2013 183
MolMed S.p.A., H1 2013 184
Viral Genetics, Inc., H1 2013 185
Immunotope, Inc., H1 2013 186
Esperance Pharmaceuticals, Inc., H1 2013 187
Omeros Corporation, H1 2013 188
Bolder Biotechnology, Inc., H1 2013 189
ImmunoVaccine Technologies Inc., H1 2013 190
Welichem Biotech Inc., H1 2013 191
Angstrom Pharmaceuticals, Inc., H1 2013 192
PharmaMar, S.A., H1 2013 194
TVAX Biomedical, LLC, H1 2013 195
Quintessence Biosciences, Inc., H1 2013 196
AmpliMed Corporation, H1 2013 197
Tigris Pharmaceuticals, Inc., H1 2013 198
Viventia Biotechnologies Inc., H1 2013 199
TRACON Pharmaceuticals, Inc., H1 2013 200
Medestea Research & Production S.p.A., H1 2013 201
Domainex Ltd., H1 2013 202
Anaphore, Inc., H1 2013 203
Oncolix, Inc., H1 2013 205
OHR Pharmaceutical Inc., H1 2013 206
Cancer Therapeutics CRC Pty Ltd, H1 2013 207
BioProspecting NB, Inc., H1 2013 208
RECEPTA Biopharma S.A., H1 2013 209
Bioo Therapeutics, H1 2013 210
Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2013 211
NovaBioMed Inc, H1 2013 212
PepTx, Inc., H1 2013 213
Mebiopharm Co., Ltd., H1 2013 214
DEKK-TEC, Inc., H1 2013 215
ISA Pharmaceuticals B.V., H1 2013 216
TAU Therapeutics, LLC, H1 2013 217
Gradalis Inc., H1 2013 218
Assessment by Monotherapy Products, H1 2013 219
Assessment by Combination Products, H1 2013 220
Assessment by Stage and Route of Administration, H1 2013 223
Assessment by Stage and Molecule Type, H1 2013 226
Ovarian Cancer Therapeutics Drug Profile Updates 280
Ovarian Cancer Therapeutics Discontinued Products 302
Ovarian Cancer Therapeutics Dormant Products 305

List of Chart


Number of Products under Development for Ovarian Cancer, H1 2013 17
Products under Development for Ovarian Cancer Comparative Analysis, H1 2013 18
Products under Development by Companies, H1 2013 19
Products under Investigation by Universities/Institutes, H1 2013 33
Late Stage Products, H1 2013 37
Mid Clinical Stage Products, H1 2013 38
Early Clinical Stage Products, H1 2013 39
Discovery and Pre-Clinical Stage Products, H1 2013 40
Assessment by Monotherapy Products, H1 2013 219
Assessment by Combination Products, H1 2013 220
Assessment by Route of Administration, H1 2013 221
Assessment by Stage and Route of Administration, H1 2013 222
Assessment by Molecule Type, H1 2013 224
Assessment by Stage and Molecule Type, H1 2013 225

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *